Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg.
Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona.
Haematologica. 2024 Feb 1;109(2):553-566. doi: 10.3324/haematol.2023.283480.
Tafasitamab, an anti-CD19 immunotherapy, is used with lenalidomide for patients with autologous stem cell transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma based on the results of the phase II L-MIND study (NCT02399085). We report the final 5-year analysis of this study. Eighty patients ≥18 years who had received one to three prior systemic therapies, and had Eastern Cooperative Oncology Group performance status 0-2 received up to 12 cycles of co-administered tafasitamab and lenalidomide, followed by tafasitamab monotherapy until disease progression or unacceptable toxicity. The primary endpoint was the best objective response rate. Secondary endpoints included duration of response, progression-free survival, overall survival, and safety. Exploratory analyses evaluated efficacy endpoints by prior lines of therapy. At data cutoff on November 14, 2022, the objective response rate was 57.5%, with a complete response rate of 41.3% (n=33), which was consistent with prior analyses. With a median follow-up of 44.0 months, the median duration of response was not reached. The median progression-free survival was 11.6 months (95% confidence interval [95% CI]: 5.7-45.7) with a median follow-up of 45.6 months. The median overall survival was 33.5 months (95% CI: 18.3-not reached) with a median follow-up of 65.6 months. Patients who had received one prior line of therapy (n=40) showed a higher objective response rate (67.5%; 52.5% complete responses) compared to patients who had received two or more prior lines of therapy (n=40; 47.5%; 30% complete responses), but the median duration of response was not reached in either subgroup. Other exploratory analyses revealed consistent long-term efficacy results across subgroups. Adverse events were consistent with those described in previous reports, were manageable, and their frequency decreased during tafasitamab monotherapy, with no new safety concerns. This final 5-year analysis of L-MIND demonstrates that the immunotherapy combination of tafasitamab and lenalidomide is well tolerated and has long-term clinical benefit with durable responses.
塔法西单抗是一种抗 CD19 免疫疗法,基于 II 期 L-MIND 研究(NCT02399085)的结果,与来那度胺联合用于不适合自体干细胞移植的复发/难治性弥漫性大 B 细胞淋巴瘤患者。我们报告了这项研究的最终 5 年分析结果。80 名年龄≥18 岁、接受过 1 至 3 种先前全身治疗且东部肿瘤协作组体能状态为 0-2 的患者接受了最多 12 个周期的联合治疗,随后接受塔法西单抗单药治疗,直至疾病进展或不可接受的毒性。主要终点是最佳客观缓解率。次要终点包括缓解持续时间、无进展生存期、总生存期和安全性。探索性分析按既往治疗线评估疗效终点。截至 2022 年 11 月 14 日数据截止时,客观缓解率为 57.5%,完全缓解率为 41.3%(n=33),与之前的分析结果一致。中位随访 44.0 个月时,中位缓解持续时间未达到。中位无进展生存期为 11.6 个月(95%置信区间[95%CI]:5.7-45.7),中位随访时间为 45.6 个月。中位总生存期为 33.5 个月(95%CI:18.3-未达到),中位随访时间为 65.6 个月。既往接受过 1 线治疗的患者(n=40)的客观缓解率(67.5%;52.5%完全缓解)高于既往接受过 2 线或更多线治疗的患者(n=40;47.5%;30%完全缓解),但在两个亚组中均未达到中位缓解持续时间。其他探索性分析显示,各亚组均有一致的长期疗效结果。不良事件与既往报告中的描述一致,且可管理,并且在塔法西单抗单药治疗期间频率降低,没有新的安全性问题。L-MIND 的最终 5 年分析结果表明,塔法西单抗联合来那度胺免疫疗法耐受性良好,具有长期临床获益,缓解持久。